Lutetium 177 PSMA enhances QOL in patients with mCRPC

"The results of this trial impacted practice globally,” says Michael J. Morris, MD.

In this video, Michael J. Morris, MD, discusses the background, findings, and takeaways of the VISION trial, which was presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.